Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 20, Issue 23, 2002, Pages 4508-4516

  Kruijtzer, C M F ^a,b,c,d,e   Schellens, J H M ^a,b,c,d,e   Mezger, J ^a,b,c,d,e   Scheulen, M E ^a,b,c,d,e   Keilholz, U ^a,b,c,d,e   Beijnen, J H ^a,b,c,d,e   Rosing, H ^a,b,c,d,e   Mathot R A A ^a,b,c,d,e   Marcus, S ^a,b,c,d,e   Van Tinteren, H ^a,b,c,d,e   Baas, P ^a,b,c,d,e,f  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b St Vincentius Kliniken   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e IVAX Research Inc   (United States)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PACLITAXEL; PAXORAL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MIDDLE AGE; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036895360     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.058     Document Type: Article

References (41)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials-Non-Small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995
2. Stewart L, Pignon JP, Arriagada R, et al: A meta-analysis using individual patient data from randomized clinical trials (RCTS) of chemotherapy in non-small cell lung cancer (NSCLC): Survival in the surgical setting. Proc Am Soc Clin Oncol 13:336, 1994 (abstr)
3. Marina P, Pampallona S, Preatoni A, et al: Chemotherapy versus supportive care in advanced non-small cell lung cancer: Results of a meta-analysis of the literature. Chest 106:861-865, 1994
4. Wozniak AJ: Single agent vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 26:62-66, 1999
5. Ten Bokkel Huinink WW, Bergman B, Chemaissanin A, et al: Single agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based therapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 26:85-94, 1999
6. Baker L, Khan R, Lynch T, et al: Phase II study of irinotecan in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:461a, 1997 (abstr 1658)
7. Socinski MA: Single agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 4:408-416, 1999
8. Miller V, Kris M: Docetaxel as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 27:3-10, 2000
9. Huizing MT, Giaccone G, Van Warmerdam LJC, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer. J Clin Oncol 15:317-329, 1997
10. Georgoulias V, Kourousis C, Kakolyris S, et al: Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: A preliminary report on an active regimen. Semin Oncol 24:S61-S66, 1997 (suppl 12)
11. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92:1074-1080, 2000
12. Fosella FV, De Vore R, Kerr RN, et al: Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
13. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998
14. Akerley W, Glantz M, Choy H, et al: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16:153-158, 1998
15. Akerley W, Herndon J, Egorin MJ, et al: CALGB 9731: Phase II study of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18:462a, 1999 (abstr 1783)
16. Kies MS, Unger O, Gillenwater HH, et al: Second-line (SL) weekly paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC) failing first-line (FL) carboplatin/paclitaxel (C/P). Proc Am Soc Clin Oncol 19:504a, 2000 (abstr 1971)
17. Sparreboom A, Van Asperen J, Mayer U, et al: Limited oral bioavailability and active epithelial excretion of paclitaxel caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94:2031-2035, 1997
18. van Asperen J, Van Tellingen O, Van der Valk MA, et al: Enhanced oral absorption and decreased elimination of paclitaxel in mice co-treated with cyclosporin A. Clin Cancer Res 4:2293-2297, 1998
19. Meerum Terwogt JM, Malingré MM, Beijnen JH, et al: Co-administration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379-3384, 1999
20. Malingré MM, Beijnen JH, Rosing H, et al: The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 12:351-358, 2001
21. Liebmann JE, Cook JA, Lipschultz C, et al: Cytotoxic studies of paclitaxel in human tumour cell lines. Br J Cancer 32:235-242, 1993
22. Raymond E, Hanauske A, Faivre SW, et al: Effects of prolonged versus short-term exposure paclitaxel on human tumor colony-forming units. Anticancer Drugs 8:379-385, 1997
23. Malingré MM, Beijnen JH, Rosing H, et al: A phase I and pharmacokinetic study of bidaily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 47:347-354, 2001
24. Therasse P, Arbuck SG, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
25. Malingré MM, Meerum Terwogt JM, Beijnen JH, et al: A phase I and pharmacokinetic study of paclitaxel. J Clin Oncol 18:2468-2475, 2000
26. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1998
27. Huizing MT, Sparreboom A, Rosing H, et al: Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatograph B Biomed Appl 674:261-268, 1995
28. Chan GL, Weinstein SS, Lefor WW, et al: Relative performance of specific and nonspecific fluorescence immunoassay for cyclosporin in transplant patients. Ther Drug Monit 14:42-47, 1992
29. Beal SL, Boeckman AJ, Sheiner LW: NONMEM Users Guide, Part VI: PREDPP Guide. San Francisco, CA, NONMEM Project GROUP, University of California, San Francisco, 1992
30. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
31. Gatzemeier U, Shepherd FA, le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 2:243-248, 1996
32. Crawford J, O'Rourke M, Schiller J, et al: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 14:2777-2784, 1996
33. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 5:1087-1100, 1998
34. Millward MJ, Bishop JF, Friedlander M, et al: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 14:142-148, 1996
35. Tester WJ, Jin PY, Reardon DH, et al: Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by a 3-hour infusion. Cancer 15:724-729, 1997
36. Ranson M, Jayson G, Perkins S, et al: Single agent paclitaxel in advanced non-small cell lung cancer: Single center phase II study using a 3-hour administration schedule. Semin Oncol 24:S12-6-S12-9, 1997 (suppl 12)
37. Gatzemeier U, Heckmayr M, Neuhauss R, et al: Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12:S101-S106, 1995 (suppl 2)
38. Huizing MT, Sewberath Misser VH, Pieters RC, et al: Taxanes: A new class of antitumor agents. Cancer Invest 13:381-404, 1995
39. Huizing MT, Keung AC, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 15:317-329, 1997
40. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
41. Myers BD, Ross J, Newton L, et al: Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699-705, 1984